Key Takeaways RMD posted Q2 EPS of $2.81, up 15.6% year over year, beating consensus alongside 11% revenue growth.Resmed expanded adjusted gross margin to 62.6% and operating margin to 36.6%, as profit outpaced costs.RMD saw double-digit growth in Sleep and Breathing Health, while Residential Care Software rose 6.6%.Resmed Inc.’s (RMD) adjusted earnings per share (EPS) in the second quarter of fiscal 2026 were $2.81, up 15.6% year over year. The metric beat the Zacks Consensus Estimate by 4.59%.The adjustme ...

Core Insights - Resmed reported strong financial results for the quarter ended December 31, 2025, with an 11% year-over-year revenue growth, driven by high demand for sleep and respiratory care devices and the expansion of its digital health ecosystem [3][5][21]. Financial Performance - Revenue for the quarter reached $1.422 billion, an increase of 11% compared to $1.282 billion in the same quarter of the previous year, with a 9% increase on a constant currency basis [4][5][21]. - Gross margin improved by 320 basis points to 61.8%, while non-GAAP gross margin increased by 310 basis points to 62.3%, attributed to manufacturing efficiencies and cost improvements [5][8][21]. - Income from operations rose by 18% to $491.7 million, with non-GAAP income from operations increasing by 19% to $517.2 million [4][5][21]. - Net income for the quarter was $392.6 million, a 14% increase from $344.6 million, with non-GAAP net income rising by 15% to $411.5 million [5][20]. - Diluted earnings per share increased by 15% to $2.68, while non-GAAP diluted earnings per share rose by 16% to $2.81 [5][20]. Operational Highlights - The company continues to invest in innovation to enhance its digital health capabilities and expand access to care [4][8]. - Operating cash flow for the quarter was $340 million, reflecting strong operational performance [5][17]. - Resmed declared a quarterly cash dividend of $0.60 per share, with a record date of February 12, 2026 [8][9]. Market Performance - Revenue growth was driven by a 11% increase in the U.S., Canada, and Latin America, while Europe, Asia, and other markets saw a 6% growth on a constant currency basis [8][21]. - The company reported a 5% increase in Residential Care Software revenue on a constant currency basis [8][21]. Strategic Initiatives - Resmed received FDA clearance for an AI-enabled digital medical device aimed at personalizing CPAP comfort settings, enhancing patient adherence [8]. - The company presented its long-term growth opportunities and leadership in digital sleep and respiratory health at the J.P. Morgan Healthcare Conference [8].

Core Insights - Resmed Inc. reported a strong start to fiscal year 2026, with a 9% year-over-year revenue growth and significant improvements in gross margins and earnings per share [2][3][5] Financial Performance - Revenue for the quarter ended September 30, 2025, was $1,335.6 million, up from $1,224.5 million in the same quarter of 2024, reflecting a 9% increase [4][5][21] - Non-GAAP gross margin improved by 280 basis points to 62.0%, while GAAP gross margin increased by 290 basis points to 61.5% [5][21] - Non-GAAP diluted earnings per share rose by 16% to $2.55, compared to $2.20 in the prior year [5][19] Operational Highlights - Income from operations increased by 15% to $446.5 million, with non-GAAP income from operations rising by 19% to $482.1 million [5][19] - Operating cash flow for the quarter was $457 million, indicating strong cash generation capabilities [5][17] - The company declared a quarterly cash dividend of $0.60 per share, payable on December 18, 2025 [8] Market and Product Insights - Revenue growth was driven by increased demand for sleep devices, masks, and accessories, with U.S., Canada, and Latin America revenue growing by 10% [9][21] - The company launched the Sleep Institute to promote sleep health as a public health priority and published a study projecting a significant increase in obstructive sleep apnea cases by 2050 [9][11] Strategic Initiatives - Resmed is committed to ongoing operational excellence and strategic investments in innovation to ensure sustainable growth [4][9] - The company recorded $16 million in restructuring-related charges as part of workforce planning aligned with its 2030 strategic priorities [9]

Core Insights - WORK Medical Technology Group Ltd. is exploring real-world asset (RWA) tokenization and blockchain technology through a partnership with the Hong Kong Web3.0 Standardization Association, aiming to leverage its existing product infrastructure and AI business [3][4][11] - The company has outlined three main areas for collaboration: tokenization of high-quality assets, equity investments, and development of RWA technology [6][7][9] Company Strategy - The partnership aligns with WORK Medical's "Healthcare + Payment + Technology = RWA + Web3 + AI" strategy, which aims to integrate various sectors for growth [4] - The company plans to collaborate with qualified firms in the financial sector to ensure compliance in its asset tokenization efforts [4] Market Potential - Tokenized RWAs are projected to exceed $50 billion by the end of the year, with U.S. treasuries expected to dominate this market, contributing over $28 billion [5] Collaboration Areas - The first area of collaboration focuses on tokenizing high-quality assets owned or invested in by WORK Medical, potentially including receivables, investment products, and intellectual property [6] - The second area involves equity investments, which may include co-investments or participation in funds to accelerate RWA tokenization [7] - The third area is the development of RWA technology, utilizing the Hong Kong Web3.0 Association's RWA registration platform for regulatory compliance and asset security [9] Recent Developments - WORK Medical has also formed a partnership with Ruijin Hospital's Wuxi Branch to advance AI-driven healthcare solutions, integrating multimodal medical data [12][13] - The company's revenue from its mask business fell 69% to $1.6 million, while revenue from other medical devices increased by 18% to $9.4 million [16] - The company generated $400,000 from commodities trading and $15.7 million from financing activities in its latest fiscal year [17]